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ABSTRACT
Drug-induced gingival hyperplasia is a serious concern both for the patient and the clinician. A 45 year-old Caucasian 
male patient with hypertension, who received amlodipine (10 mg/day, single dose orally) for two months, sought medical 
attention because of the new-onset gingival enlargement. On clinical examination a generalized and firm overgrowth 
of the gingival throughout the maxilla and the mandible were evident. The lack of gingival inflammation and purulent 
discharge were other features of the clinical scenario. Histological assessment of the biopsy specimen revealed the hy-
perplasia of connective tissue, epithelial acanthosis, and elongated rete ridges along with few inflammatory cells. The 
histological and the clinical evidences were consistent with amlodipine-induced gingival hyperplasia. We believe that the 
present report indicates the most rapidly developed case of amlodipine-induced gingival hyperplasia reported to date. 
The related literature is reviewed and the underlying pathogenic mechanisms of this rare side-effect are discussed here.
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INTRODUCTION
Gingival hyperplasia due to the concomitant unesthetic 
appearance and the formation of new niches for the pe-
riopathogenic bacteria (1) is considered a serious adverse 
drug reaction. Acanthosis of epithelial lining, elongation 
of rete ridges, and sparse fibroblasts in a dense collagenous 
matrix are the underlying histological changes. Three main 
classes of drugs known to cause GH are anticonvulsants 
(2), antihypertensive calcium antagonists (3) and the immu-
nosuppressant cyclosporine (4). Despite the relatively high 
prevalence of nifedipine-induced gingival hyperplasia (3), 
amlodipine has rarely been reported as the potential etio-
logic cause of gingival hyperplasia (3,5,6). We presented a 
rare case of amlodipine-induced gingival hyperplasia along 
with the review of relevant literature. 
    
CASE REPORT
A 45 year-old Caucasian male patient referred to the de-
partment of periodontics at Tabriz University of Medical 
Sciences complaining of  “swollen gums”. Past medical 
history was remarkable for a newly-diagnosed hyperten-
sion for which the patient received amlodipine (10 mg/day, 
single dose orally) for the last two months. The patient had 
noted a gradual and painless enlargement of the gingiva 
of three weeks duration. Physical examination revealed a 
young man who was well-doing and in no acute distress. A 
generalized and firm overgrowth of the gingiva was found 
throughout the maxilla and mandible particularly at the 
buccal side (Fig. 1). The lack of periodontal pockets (mean 
probing depth: 2.4 mm, SD: 1.2) was a prominent feature 
of gingival overgrowth indicating an outward rather than 
vertical enlargement of gingiva. No changes in the gingival 
color, purulent discharge and bleeding on probing were de-
tected which were in accordance with the lack of the gingival 
inflammation. Examination was otherwise unremarkable. 
Microscopic inspection of the gingival biopsy specimens 
demonstrated a connective tissue hyperplasia, acanthosis of 
overlying epithelium, and elongated rete ridges together with 
few sparse inflammatory cells. The lesion was diagnosed as 
amlodipine-induced gingival hyperplasia based on clinical 
and histological evidences.
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DISCUSION
Gingival hyperplasia with its potential cosmetic implications 
and also providing new niches for the growth of microorga-
nisms is a serious concern for both the patients and clinician. 
Calcium channel blockers are considered potential etiologic 
agents of drug-induced gingival hyperplasia. Although the 
incidence of nifedipine-induced gingival hyperplasia is about 
10% (3), very few reports of amlodipine-related gingival 
hyperplasia does exist in the extant literature (3,5,6). In a 
series of 150 cardiac patients, it was found that amlodipine at 
a dose of 5 mg/day can not induce gingival hyperplasia even 
if taken more than 6 months (6). Contrarily, Seymour et al. 
reported three patients with poor periodontal conditions who 
developed gingival hyperplasia upon a chronic usage (at least 
three moths) of amlodipine (3). Our patient had a favorable 
oral condition and received a rather low-dose of amlodipi-
ne for only two months. We believe that the present report 
indicates the most rapid-onset case of amlodipine-induced 
gingival hyperplasia reported to date.  
The underlying mechanism remains to be fully understood. 
However, two main inflammatory and non-inflammatory 
pathways have already been suggested. The proposed non-in-
flammatory mechanisms include defective collagenase activity 
due to decreased uptake of folic acid (7), blockage of aldos-
terone synthesis in adrenal cortex and consequent feedback 
increase in ACTH level (8), and upregulation of keratinocyte 
growth factor (KGF) (9). Alternatively, inflammation may 
develop as a result of direct toxic effects of concentrated drug 
in crevicular gingival fluid (CGF) and/or bacterial plaques 
(10). This inflammation could lead to the upregulation of 
several cytokine factors such as TGF-ß1 (11). 
In the present case the lack of inflammatory component 
parallels the absence of vertical gingival growth and conse-
quently the lack of periodontal pockets or pseudopockets. 
We hypothesize that the formation of pocket/pseudopocket 
assembly is a phenomenon that is associated with gingival in-
flammation. So that, TGF-ß1 and other factors responsible 
for the production of a fibrous scaffold may be essential for 
the vertical growth of gingiva –pseudopocket development- 
and also the formation of periodontal pockets necessitates 
the inflammatory degradation of the periodontal tissues. As 
an alternative, periodontal pocket formation may precede 
the inflammation.
Finally, we emphasize that gingival hyperplasia could be a 
side effect of amlodipine even with a very short term and 
low dose administration. 
Fig. 1. Clinical presentation of gingival hyperplasia. Figures A and B show the left and right sides, respectively. Figures C and D are 
the maxillary and mandibular views, respectively.
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